Form 8-K - Current report:
SEC Accession No. 0001372514-25-000050
Filing Date
2025-06-03
Accepted
2025-06-03 07:00:35
Documents
14
Period of Report
2025-05-30
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K kprx-20250530.htm   iXBRL 8-K 30944
2 EX-10.1 ex101-kioraxsenjuoptionagr.htm EX-10.1 130946
3 EX-99.1 ex991-pressrelease06032025.htm EX-99.1 14867
  Complete submission text file 0001372514-25-000050.txt   325353

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT kprx-20250530.xsd EX-101.SCH 1800
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT kprx-20250530_lab.xml EX-101.LAB 22548
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT kprx-20250530_pre.xml EX-101.PRE 13058
16 EXTRACTED XBRL INSTANCE DOCUMENT kprx-20250530_htm.xml XML 2810
Mailing Address 332 ENCINITAS BOULEVARD SUITE 102 ENCINITAS CA 92024
Business Address 332 ENCINITAS BOULEVARD SUITE 102 ENCINITAS CA 92024 781-788-8869
KIORA PHARMACEUTICALS INC (Filer) CIK: 0001372514 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36672 | Film No.: 251017134
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)